A Pilot Study in North Louisiana to Assess the Tolerability of Psilocybin as Well as Its Capacity to Promote Abstinence From Methamphetamine
The primary purpose of this study is to preliminarily determine if the use of psilocybin to promote abstinence from methamphetamine is feasible and well tolerated in populations such as those found in Northern Louisiana. Investigators will assess the impact of psilocybin-facilitated treatment on methamphetamine abstinence, craving, negative affect, cognitive function and quality of life. Components of the psilocybin experience will also be measured (persisting effects, quality of life, challenging experiences, etc). Investigators will assess feasibility and tolerability as rates of retention and challenging experiences, among other factors.
- Status
- recruiting
- Phase
- Early Phase 1
- Institution
- Kevin Murnane
- Principal investigator
- Kevin S Murnane, PhD
- Start date
- 2025-04-04
- End date
- 2027-03-01
- Registry ID
- NCT06899594
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.